Atlas Trials

Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma

Clinical trial NCT07508605 · RECRUITING

Trial details

NCT number
NCT07508605
Sponsor
Shenzhen University General Hospital
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapsed/Refractory B-cell Lymphoma
Start date
2025-01-01
Primary completion
2027-12-30
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.